Flash in the pan revenues. No company wants to have this press: Gilead Sciences Inc. will continue to feel the financial sting this year of declining revenues

Flash in the pan revenues. No company wants to have this press: Gilead Sciences Inc. will continue to feel the financial sting this year of declining revenues from its hepatitis C business, forecasting combined 2018 sales of the drugs reaching only a fifth of what the biotech recorded at the height of its commercial success three years ago. https://www.biopharmadive.com/news/gilead-hepatitis-c-revenues-slide-fourth-quarter-earnings/516494/ https://www.biopharmadive.com/news/gilead-hepatitis-c-revenu... Contrast a statin for Pfizer: $125 billion in sales over 14 years. Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years." https://en.wikipedia.org/wiki/Atorvastatin#History https://en.wikipedia.org/wiki/Atorvastatin#History